泛素蛋白-D在术后化疗的Ⅱ期结肠癌患者中的表达及临床意义  

The positive ubiquitin D expression predicts poor survival in postoperative stage II colon cancer patients treated with postoperative adjuvant chemotherapy

作　　者：赵森林[1] 唐华美[2] 崔菲菲[1] 陈健[1] 陆惠军 薛英明[1] 彭志海[1] 严东旺[1] 

机构地区：[1]上海交通大学附属第一人民医院普外科,200080 [2]上海交通大学附属第一人民医院病理科,200080

出　　处：《中华普通外科杂志》2014年第5期358-361,共4页Chinese Journal of General Surgery

基　　金：国家自然科学基金资助项目（81172328,81220108021）;上海市科委生药领域资助项目（124119a1700,11431921000）;上海市市级医院新兴前沿技术联合攻关项目（SHDC12012105）;上海市产业技术研究院项目（12DZ942500）;上海交通大学“医工（理）交叉研究基金”项目（YG2012ZD01）

摘　　要：目的探讨人泛素蛋白-D（UbiquitinD，UBD）在接受术后以5-氟尿嘧啶为基础的辅助化疗的Ⅱ期结肠癌患者中的表达及其临床意义。方法随机选取106例接受术后以5-氟尿嘧啶为基础的辅助化疗的Ⅱ期结肠癌患者，根据有无复发分为：复发组（35例）和未复发组（71例）。从两组患者中分别随机选取20例Ⅱ期结肠癌肿瘤组织和配对的正常组织，采用实时定量聚合酶链反应（real—timePCR）检测UBD基因的mRNA表达量，用免疫组织化学方法检测UBD基因在化疗后35例复发和71例未复发患者癌组织及相应正常组织中蛋白表达量。用χ2检验比较计数资料之间差异，通过COX比例风险模型评估风险。结果复发组和未复发组肿瘤组织中UBDmRNA的平均表达量分别是7．64及2．87（χ2=10．7，P〈0．01）。免疫组织化学结果显示UBD在复发和未复发患者肿瘤组织中阳性表达率分别为86％（30／35）及59％（42／71）（χ2=7．59，P〈0．01）。UBD阳性者化疗后5年无瘤生存率（P〈0．05）和总体生存率（P〈0．05）均显著降低。结论UBD基因表达是影响Ⅱ期结肠癌患者化疗后无瘤生存率和总体生存率的独立预后因素。Objective To investigate the expression of human ubiquitin D （UBD） and its role in tumor relapse and non-relapse group patients who received 5- fluoruracil -based adjuvant chemotherapy after surgery. Methods In this study 106 stage Ⅱ patients treated with postoperative 5-fluoruracil（5-fu） -based adjuvant chemotherapy were enrolled, and divided into two groups： recurrence group （35 cases） and non- recurrence group （71 cases）. The expression of UBD mRNA was detected by real-time quantitative polymerase chain reaction （real-time PCR） in respective 20 matched cancer and normal colonic membrane tissues of stage Ⅱ colon cancer patients in the two groups, hnmunohistochemistry was used to study UBD expression in 35 patients with recurrence and 71 non-relapse patient＇s cancer and normal tissues. Chi-square test or Fisher＇s exact test were used and evaluated the hazard ratio （HR） of disease-free survival（DFS） and overall survival（OS） by using Cox proportional hazard model. Results The average expression level of UBD mRNA in 20 relapse and non-relapse group patients were 7.64 and 2. 07 （ χ2 = 10. 7, P 〈 0. 01 ） , respectively; UBD positive staining in relapse and non-relapse group patients were 86% （30/35） , and 59% （42/71） （χ2= 7.59 ,P 〈 0. 01 ）. The 5-years DFS （P 〈 0. 05） and OS （P 〈 0. 05） decreased significantly in UBD positive cases. Conclusions UBD is an independent prognostic factor for DFS and OS in postoperative StageⅡ colonic cancer patients treated by post oprative chemotherapy.

关 键 词：泛素类 结肠肿瘤 抗肿瘤 联合化疗方案 

分 类 号：R735.35[医药卫生—肿瘤]